Fig. 5: Synergistic activity of ABT-263 and Navelbine in PDX-model and human lung cancer patient.
From: Predicting and affecting response to cancer therapy based on pathway-level biomarkers
a Cell viability in ex-vivo organ culture. Viability values are as follows: 0: 0–20% viability, complete response; 1: 20–35%, partial response: strong; 2: 36–59%, partial response: moderate; 3: 60–84%, partial response: weak; 4: 85–100%, no response. Viability percentages were quantified by evaluating morphological features and were performed by two pathologists that were blinded to the experiment. b H&E-stained histology of NSCLC PDX tumors treated ex-vivo with DMSO (control), Navelbine, ABT-263, and a combination of the two drugs. c H&E-stained histology of a tumor from an untreated 71-year-old patient. The samples treated ex-vivo with DMSO (control), Navelbine, ABT-263, and a combination of the two drugs. d AIF pathway activity levels calculated from qRT-PCR in FFPE-preserved tissues from (b). P-values were generated using Mann–Whitney U-test. e AIF pathway activity levels calculated from qRT-PCR in FFPE-preserved tissues from (c) before and after treatment with a combination of navelbine and ABT-263. P-values were generated using Mann–Whitney U-test. See also Supplementary Fig. 7b.
